Biopharma
ByAbbVie Accelerates Portfolio-Led Growth in 2025 and Strengthens Its Long-Term Therapeutic Leadership
North Chicago, IL – February 2026 – AbbVie Inc. reported a strong full-year financial performance in 2025, underscoring…
Did Abivax Just Quash Acquisition Rumors by Eli Lilly — and What It Means for Its IBD Breakthrough Asset?
January 26, 2026 — Paris & Global — Abivax SA, the French clinical‑stage biotechnology company, this week publicly dismissed speculation…
Could Sun Pharma’s Bold Bid for Organon Redefine Its U.S. Strategy and Global Footprint?
January 25, 2026 — Mumbai & New York — Sun Pharmaceutical Industries Ltd. (Sun Pharma), India’s largest pharmaceutical company, has…
Can GSK’s New Leadership Translate into Multi-Franchise Growth in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Vaccines, Immunology & Specialty Care GlaxoSmithKline (GSK) is set…
Gilead’s $8B Arcellx CAR-T Swoop & Lilly Zepbound Triumph: Obesity/CAR-T Mania or Bubble Burst Ahead?
Gilead’s March 2026 $8B acquisition of Arcellx—securing CAR-T anito-cel for multiple myeloma with 73% ORR Phase 1b data—and…
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab (asthma) and GSK’s…
